GlassScriptPhysician profile
Jenna Williams
NPI 1962818468
$1,203.32
in general payments reported to CMS, 2019-2025
16 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $75.80 · 2023: $79.82 · 2024: $435 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $315.22 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $145.74 | 2023-2024 | Rexulti |
| Celgene Corporation | $121.66 | 2023-2025 | Breyanzi, Pomalyst |
| Kite Pharma, INC. | $115.73 | 2025 | |
| Janssen Scientific Affairs, LLC | $93.75 | 2021 | |
| Novo Nordisk INC | $90.17 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $62.75 | 2021-2025 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $61.69 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.55 | 2025 | Caplyta |
| Mallinckrodt Hospital Products INC. | $36.23 | 2024 | Acthar |
| Sobi, INC | $26.62 | 2024 | |
| Dexcom, INC. | $24.01 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $21.70 | 2021 | |
| Organon LLC | $14.11 | 2022 | |
| Pfizer INC. | $14.06 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.